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膵管内乳頭粘液性腫瘍（IPMN）術後の糖代謝の経過
についての検討
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Intraductal papillary mucinous neoplasm (IPMN) generally has a better prognosis than pancreatic ductal car-
cinoma. Therefore, postoperative diabetes mellitus (PODM) should be managed effectively. We investigated the
glucose intolerance and treatment of diabetes before and after pancreatectomy in patients with IPMN. In our hos-
pital, 160 patients underwent pancreatectomy, and only 96 were followed up. Twenty patients (21 %) had preop-
erative diabetes. Among the 59 patients who underwent pancreatectomy, 21 (59 %) had newly developed PODM.
The preoperative HbA1c level was significantly higher (6.0 [5.8-6.3]% vs. 5.7 [5.6-5.9]%) in the PODM group than in
the other groups. The incidence of PODM in patients undergoing pancreatic tail or body and tail resection (distal
pancreatectomy) was significantly higher than that in those undergoing pancreatic head, body or body and tail,
and uncinated process resection (tail, 60 %; head, 32 %; body or body and tail, 13 %; vs. uncinated process, 0 %). Pa-
tients requiring insulin therapy were older and had higher preoperative HbA1c levels. The rate of requiring insu-
lin therapy was higher in patients undergoing tail or body and tail resection (tail or body and tail, 39 %; head, 21 %;
body 0 %; vs. uncinated process, 0 %). These results suggest that development of PODM in patients with impaired
preoperative glucose tolerance and those who have undergone pancreatic tail or body and tail resection should be
closely monitored.
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癌，非浸潤性（intraductal papillary mucinous carci-
noma：IPMC，noninvasive），膵管内乳頭粘液性腺






























訳を Fig. 1に示す．術前からの糖尿病合併は 20名
（21％）で術式別の内訳は，全摘例 23名中 6名，膵
















Table　1　Comparison of clinical backgrounds of patients with and without postopera-
tive diabetes mellitus after pancreatic operation, excluding those who have under-
gone total pancreatectomy
Postoperative diabetes mellitus ＋(n＝21)
－
(n＝38) p
Age at operation (years) 66 [60-72] 62 [55-68] 0.169
Sex (male/female) 8/14 20/18 0.286
Years after operation 5.4 [4.3-6.7] 5.2 [3.6-7.7] 0.824
Preoperative HbA1c level (%) 6.0 [5.8-6.3] 5.7 [5.6-5.9] 0.0001
Portion of pancreatectomy
(head/tail or body and tail /body/uncinated process) 11/9/1/0 23/6/7/2 0.050
IPMN form
(mixed type/main duct type/branch duct type) 2/6/13 5/8/25 0.777
IPMN histological classification
(IPMA/noninvasive IPMC /IPMC invasive) 14/4/3 20/14/4 0.362
IPMA; intraductal papillary mucinous adenoma, IPMA noninvasive; intraductal papillary muci-
nous carcinoma, noninvasive, IPMA invasive; intraductal papillary mucinous carcinoma, inva-
sive.
Age at operation, sex, IPMN form, and histological classification were insignificantly different 
between patients with and without postoperative diabetes mellitus. Preoperative HbA1c levels 
significantly increased in patients with postoperative diabetes. 
Fig.　1　Glucose intolerance and treatment of diabetes before and after pancreatectomy in 
patients with IPMN
Of the 96 patients who underwent surgery, 20 (21%) had been diagnosed with preopera-
tive diabetes. Of the 73 patients who underwent pancreatic resection, 59 had no preop-
erative diabetes. Approximately 5.3 [4.0-6.9] years after pancreatic resection, 21 of the 59 
patients (36%) had diabetes.
Post-op, postoperative; OHA, oral hypoglycemic agents.
Post-op treatment for diabetes
Insulin therapy n=16
OHA                     n= 8
No medication n=11
Post-op treatment for diabetes
































Post-op treatment for diabetes
Insulin therapy n=12
OHA                     n=0
No medication n=2
Post-op treatment for diabetes
Insulin therapy n=4
OHA                      n=8
No medication n=9
Patients who underwent
glucose tolerance test    n=20
Patients who underwent
glucose tolerance test    n=10
61
―E195―
Table　2　Comparison of preoperative glucose tolerance test results between patients 
with and without postoperative diabetes mellitus




(head/tail or body and tail/uncinated process) 7/3/0 15/3/2 0.396
IPMN form
(mixed type/main duct type/branch duct type) 1/3/6 2/3/15 0.677
75 g Glucose tolerance test
　Normal/boarderline/DM type 2/3/5 12/8/0 0.286
　Fasting blood glucose (mg/dl) 106 [99-114] 96 [90-101] 0.01
　1-h blood glucose (mg/dl) 223 [201-239] 167 [140-177] 0.0004
　2-h blood glucose (mg/dl) 190 [137-247] 134 [108-164] 0.042
　Fasting insulin (μU/ml) 6.3 [4.1-11.4] 4.4 [3.1-5.7] 0.058
　1-h insulin (μU/ml) 45.6 [38.6-50.3] 52.4 [29.8-95.2] 0.554
　2-h insulin (μU/ml) 52.3 [30.1-96.1] 40.5 [26.3-56.1] 0.253
Insulinogenic index＊ 0.34 [0.25-0.43] 0.69 [0.45-1.44] 0.0064
＊Insulinogenic index (1-hour)＝serum insulin (1-h fasting) /⊿Blood glucose (1-h fasting).
In patients with postoperative diabetes mellitus, blood glucose levels were significantly higher. 
The blood glucose level 1-h after loading was particularly high; and the insulinogenic index was 
significantly low.
Table　3　Clinical background studied based on the part of the pancreas that underwent pancreatectomy













Age at operation (years) 65 [57-69] 67 [62-71] 60 [55-66] 70 [62-78] 0.260 
Sex (male/female) 24/19 6/12 5/5 1/1 0.456
Preoperative HbA1c level (%) 5.9 [5.7-6.3] 5.9 [5.7-6.6] 5.7 [5.5-6.0] 5.9 [5.6-6.1] 0.141
Years after operation 5.4 [4.0-7.1] 4.5 [3.5-5.6] 5.1 [3.9-7.9] 5.8 [3.0-8.5] 0.538
Onset of diabetes (pre-op/post-op/none) 9/11/23 3/9/6 2/1/7 0/0/2
IPMN form
(mixed type/main duct type/branch duct type 5/9/29 2/6/10 1/2/7 0/0/2 0.822
IPMN histological classification)
(IPMA/IPMC noninvasive/IPMC invasive) 21/16/6 14/1/3 6/4/0 2/0/0 0.194
Ope, operation.
























Table　4　Comparison of clinical backgrounds of patients with and without insulin therapy 




Age at operation (years) 70 [68-74] 63 [57-68] 0.002
Sex (male/female) 9/7 28/30 0.572
Years after operation 5.2 [4.2-6.5] 5.3 [3.9-7.5] 1.000
Diabetes before operation (n) 12 2 0.0001
Preoperative HbA1c level (%) 7.2 [6.2-8.1] 5.8 [5.6-6.0] 0.0001
Part of pancreas that underwent pancreatectomy
(head/tail or body and tail /body/uncinated process) 9/7/0/0 34/11/10/2 0.059
IPMN form
(mixed type/main duct type/branch duct type) 2/5/9 6/12/40 0.616
IPMN histological classification
(IPMA/IPMC noninvasive/IPMC invasive) 10/3/3 33/19/6 0.444
In the insulin therapy group, patients were significantly older with high preoperative HbA1c values.
Fig.　2　The incidence of newly onset diabetes mellitus after pancreatic operation (Fig. 2A) 
and ratio of insulin therapy as postoperative treatment (Fig. 2B), examined based on the 
part of pancreas that underwent pancreatectomy.
Dark-colored column in Fig. 2A shows the incidence of new onset diabetes mellitus 
among patients who underwent pancreatectomy, excluding those diagnosed with preop-
erative diabetes. Dark-colored column in Fig. 2B shows patients taking insulin therapy 
among those who underwent pancreatectomy. The incidence of new onset diabetes and 
ratio of insulin therapy were highest among patients who underwent tail or body and 
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